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Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) is an uncommon but potentially life threatening
disease in children. Pulmonary hemorrhage (PH) is a well recognized but lethal complication. The incidence of
venous thromboembolism (VTE) is higher in patients with AAV, especially in those with active disease. However,
the simultaneous occurrence of both PH and VTE has rarely been reported.
Herein, we describe a 14-year-old female with AAV who developed concomitant deep vein thrombosis (DVT) and PH
within 3 days after hospitalization. She was successfully treated with timely plasmapheresis and methylprednisolone pulse
therapy. VTE did not occur during discontinuation of anticoagulant. On reviewing the English literature, 5 AAV patients with
coexisting VTE and PH have been reported. When faced with PH, whether or not to keep anti-coagulation treatment is a
dilemma. Some of the patients kept receiving anti-coagulation treatment, whereas others undergoing inferior vena
cava filter implantation. Glucocorticoids and cyclophosphamide or other immunosuppressant agents were prescribed
in all patients. All of the cases survived after treatment for concurrent VTE and PH, and received short- or long-term
anticoagulation treatment after discharge.
To the best of our knowledge, this is the first report of a pediatric patient with AAV presenting with coexistent VTE and
PH. VTE should be considered to be a sign of disease flare-up, and early plasmapheresis with immunosuppressant therapy
can rescue this fatal complication.
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Antineutrophil cytoplasmic antibody-associated vasculitis
(AAV) is rare but severe disease in children. It is a multi-
system disease that involves the lung, skin, kidney, ears,
nose, and throat. Pulmonary hemorrhage (PH) is a well
recognized but lethal complication [1, 2]. The incidence
rate of PH in patients with AAV is about 8-36 % [3]. The
mortality rate of AAV associated PH has been reported to
range from 18 % to 50 % within 1 year even under ad-
equate treatment or mechanical ventilation [3]. Compared
to PH, venous thromboembolism (VTE) is less well de-
scribed. The mortality rate for AAV related VTE has been
reported to be about 0–15.4 %, and most cases die of right* Correspondence: long@adm.cgmh.org.tw
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unless otherwise stated.heart failure related to fulminant pulmonary embolism
(PE) [4–6]. Treatment outcome and long-term prognosis
are related to early diagnosis, proper assessment of disease
severity, and adequate induction remission therapy. More
aggressive and timely treatment is essential especially fa-
cing life-threatening complications. Both VTE and PH
have a higher incidence with increasing disease activity
[4], but reports of the coexistence in patients with AAV
are very rare. Herein, we present the first reported case of
childhood-onset AAV complicated with deep vein throm-
bosis (DVT) and concurrent PH. We describe the chal-
lenges in therapeutic management for these coexisting
complications.Case presentation
This 14-year-old female was relatively healthy before this
presentation without systemic diseases. She was first ad-
mitted to our hospital due to fever, hemoptysis, anemiaThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Tseng et al. Pediatric Rheumatology  (2015) 13:20 Page 2 of 7with a hemoglobin level of 4.2 g/dL and hyperpigmented
macula on her legs. High resolution computed tomography
revealed PH, as shown in Fig. 1. Her clinical symptoms
were response well to initial management including empiric
antibiotics and blood transfusion, and no hemoptysis,
anemia and fever were noted after the third hospital day.
Serial examinations to survey the etiology of PH, including
ruling out infections such as tuberculosis and viruses, vas-
culitis and other autoimmune diseases, coagulopathy and
cardiac-related conditions were performed. On the sixth
hospital day, serum anti-myeloperoxidase antibody (MPO-
ANCA) results were found to be positive. The diagnosis of
ANCA-associated vasculitis was established by the findings
of a skin biopsy which showed leukocytoclastic vasculitis
with negative immunofluorescence staining (Fig. 2). Renal
biopsy was not performed because of normal serum cre-
atinine level and mild proteinuria. Due to her family’s con-
cerns of the side effects of cyclophosphamide such as
gonadal suppression and infertility, we administered oral
prednisolone (1 mg/kg/day) and oral mycophenolate mofe-
til (250 mg twice daily) to induce remission. At the end of
the first hospitalization, chest radiograph revealed bilateral
clear lung fields without patchy infiltration. She was dis-
charged after 12 days of hospitalization.
Five days after discharge, she was admitted to our hos-
pital again due to 2-day-history of swollen right lower limb.
There were no fever, hemoptysis, cough, pleuritic chest
pain, cyanosis or dyspnea, however skin rash was noted on
her right leg. Her blood pressure was 112/85 mmHg with a
heart rate of 79/min with a regular rhythm and her respira-
tory rate was 18 per minute with a body temperature of
37.1 °C on admission. On physical examination, swelling
with different calf diameters, warmth, erythema, and posi-
tive Homan’s sign of right lower extremity, as well as mul-
tiple purpura over her right leg with local tenderness wereFig. 1 High resolution computed tomography with contrast medium show
right side than the left sidenoted. Chest, abdominal, and neurological examinations re-
vealed no abnormal findings. The initial chest radiograph
was normal without patch infiltrates, effusion, hemidiaph-
ragm, Hampton hump or Westermark sign. The laboratory
findings showed hemoglobin level of 9.1 g/dL, platelet
count of 390,000/uL, white blood cell count of 12,800/
mm3, international normalized ratio of 0.9, and D-dimer
level of 2048 FEU ng/mL, blood urea nitrogen 30.6 mg/dL,
creatinine 0.76 mg/dL, C-reactive protein 2.41 mg/L,
albumin 3.33 g/dL and mild to moderate proteinuria. A
Doppler ultrasound scan of her lower limbs showed a
thrombus at the right common femoral vein. There were
no other classic risk factors for DVT, and investigations of
hypercoagulable status including anti-cardiolipin antibody,
anti-β-glycoprotein antibody, lupus anti-coagulant, anti-
thrombin III, protein C, and protein S were all within nor-
mal ranges. Under the diagnosis of DVT, subcutaneous low
molecular weight heparin (enoxaparin; 30 mg twice daily),
in addition to intravenous methylprednisolone and myco-
phenolate mofetil were delivered. Due to lack of associated
clinical symptoms, PE was not considered. Her palpable
purpura and leg swelling improved 2 days after admission.
However, she suddenly experienced hemoptysis and a
decreased hemoglobin level on the third hospital day.
Laboratory studies did not show coagulopathy or
thrombocytopenia, and chest radiograph demonstrated
diffuse ground glass appearance mixed with multiple
patch consolidation on both lung fields. Due to con-
cerns of PH, enoxaparin was discontinued to prevent
further exacerbation of bleeding. Methylprednisolone
pulse therapy (30 mg/kg/day) was given immediately to
control the active AAV. However, the diffuse alveolar
hemorrhage exacerbated with the consequent develop-
ment of hypoxemia, hemoptysis, and dyspnea. She was
intubated with ventilator support due to progression ofed patchy inhomogeneous opacities in bilateral lungs, more on the
Fig. 2 A skin biopsy revealed leukocytoclastic vasculitis in small-sized vessels in the upper dermis. Perivascular infiltrates with neutrophils, nuclear
dust, and red blood cells were identified, consistent with leukocytoclastic vasculitis
Tseng et al. Pediatric Rheumatology  (2015) 13:20 Page 3 of 7PH on the sixth hospital day. Aggressive plasmapheresis was
administered to remove excessive auto-antibodies. Support-
ive care with frequent blood transfusions and bronchoscope
to remove clots were also given. An inferior vena cava filter
was not considered due to resolving DVT and the concerns
of a high risk with anesthesia in her critical condition. The
PH resolved within 1 week after the initiation of these inter-
ventions, and she was extubated successfully on the 13th
hospital day. No further hemoptysis or cough was noted
during the rest of the hospitalization.
Neither DVT nor PE recurred after withdrawing the
anticoagulants. To prevent further VTE, we added war-
farin on the 20th hospital day. Intravenous cyclophos-
phamide (500 mg/m2) was administered thereafter. She
was discharged with oral cyclophosphamide (1.5 mg/kg/
day) and oral prednisolone (1 mg/kg/day). We planned
to prescribe wafarin for at least 6 months if without re-
currence of VTE.
She was symptom-free after discharge without hemoptysis,
cough, chest pain or swollen leg. Her consciousness was
clear without any abnormal neurological signs. Warfarin
was prescribed and target level of international normalized
ratio between 2 to 2.5 was maintained. However, she devel-
oped a sudden coma 3 weeks after the second discharge,
and brain MRI revealed diffuse subarachnoid hemorrhage
which favored cerebral vasculitis. After methylprednisolone
pulse therapy and rituximab, she survived but in a vegetative
state after that episode. We have followed this patient for 2
more years, and no PE, VTE or other relapse has occurred.
Literature review
We searched PubMed, Medline, and Cochrane data-
bases for literature published between 1980 and December
2014 in English, using the keywords “ANCA-associatedvasculitis”, “thromboembolism”, and “pulmonary hemor-
rhage”. We also scanned the references of all included art-
icle for additional studies.
Only 5 cases of coexisting PH and VTE in patients
with AAV were found. Table 1 shows the general charac-
teristics, clinical presentations, and therapeutic interven-
tions of these 5 patients and our patient [7, 8]. Three of
these cases (50 %) were female and the mean age at
diagnosis of AAV with coexisting PH and VTE was
36.3 years (range, 14–61 years). Beside renal manifesta-
tions, ears, nose, and throat (67 %), central nervous sys-
tem (33 %), and skin (33 %) were the most commonly
involved organs. One case presented with dermatomyo-
sitis, and our case presented with palpable purpura.
Among these patients, 67 % had positive PR3-ANCA
autoantibody, while only 33 % had positive MP3-ANCA
autoantibody.
Most patients with VTE had both PE and DVT (3 of 6,
50 %). Two patients had only PE, and our case had only
DVT. With regards to the time sequence, 3 of these 6 pa-
tients had VTE prior to the episode of PH with an interval
of 5 to 14 days. Simultaneous episodes of PH and VTE were
noted in 2 patients. Only 1 patient had PH before VTE.
With regards to the therapeutic management of AAV,
all patients received glucocorticoids, and 4 patients (67 %)
received additional cyclophosphamide. Other immuno-
suppressant agents were prescribed instead of cyclophos-
phamide in 2 cases; 1 received mycophenolate mofetil,
and the other who had the involvement of 5 organs re-
ceived rituximab plus IVIG. Plasmapheresis was per-
formed in 4 patients (67 %) after diagnosis of PH. When
facing VTE with concurrent PH, the therapeutic manage-
ment and considerations in these patients were all differ-
ent. There were 2 cases with simultaneous PH and VTE,
Table 1 Reported Cases of coexistent pulmonary hemorrhage and venous thromboembolism in patients with AAV








AC IVC filter Outcome
1 Sousa et al. [7] 48(F) Renal, ENT PR3-ANCA Simultaneous PH and PE Y(1g) No MMF Y(5) No Y Survived, Recurrent PE, Long
term AC
2 Sousa et al. [7] 19(F) Renal, ENT PR3-ANCA Simultaneous PH and multiple PE’s,
Upper limb DVT
Y(3g) Y No No UFH No Survived, Short-term AC
3 Sousa et al. [7] 61(M) Renal, ENT, CNS,
Skin
MPO-ANCA PH 2 weeks after multiple PE’s Y(3g) No Rituximab,
IVIG
Y(5) LMWH Y Survived, Pulmonary fibrios,
Short term AC
4 Sousa et al. [7] 45(M) Renal, ENT PR3-ANCA PH 1 week before multiple PE’s and
Lower limb DVT
Y(3g) Y No No LMWH Y Survived, CKD stage 3, Long
term AC
5 Dreyer et al. [8] 31(M) Renal PR3-ANCA PH 1 week after Lower limb DVT and PE Y(1.5g) Y No Y(5) UFH Y Survived, Short-term AC
6 Our case 14(F) Renal, Skin MPO-ANCA PH 5 days after right lower limbs DVT Y(3g) Y MMF Y(5) LMWH N Survived, Short-term AC
M, male; F, female; Y, yes; ENT, ear, nose and throat; CNS, central nervous system; PE, pulmonary embolism; PH, pulmonary hemorrhage; DVT, deep vein thrombosis; CYC, cyclophosphamide; MMF, mycophenolate
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stead of anticoagulant, and the other took unfractionated
heparin without an inferior vena cava filter. Three patients
had VTE prior to PH, and they all received anticoagulants
after a diagnosis of VTE. When PH was noted, 1 case re-
ceived low-molecular weight heparin continuously, and
also insertion of an inferior vena cava filter. Another case
received an inferior vena cava filter first, followed by anti-
coagulant. In our case, we discontinued the anticoagulants
when PH was noted with no implantation of an inferior
vena cava filter, and began prophylactic anticoagulant
treatment thereafter.
Even though three of these patients were admitted to in-
tensive care unit for mechanical ventilation and other sup-
portive care, all of the 6 patients survived after treatment.
Four of the 6 patients received short-term anticoagulation
treatment to prevent further VTE, and the other 2 pa-
tients received long-term anticoagulant treatment.
Discussion
AAV is uncommon in childhood with an annual incidence
of 0.24 per 100,000 children [2]. The incidence of PH in
patients with AAV has been reported to range between
8 % and 36 % [3], while the incidence of VTE associated
with AAV was less common [4]. Timely diagnosis and ag-
gressive treatment for AAV is essential, especially when fa-
cing a life-threatening complication such as PH. There are
rare reports of PH and VTE occurring simultaneously.
Our patient is the first reported case of childhood-onset
AAV complicated with PH and concurrent DVT. She was
successfully treated with timely aggressive therapy with
plasmapheresis and methylprednisolone pulse therapy,
and both PH and VTE improved after the intervention.
The incidence of VTE increases during active AAV. A
prospective study by Merkel et al. showed the incidence
of VTE in patients with Wegener’s granulomatosis was
7.0/100 person-years compared to an incidence of 0.3/
100 person-years in the general [9]. In another retro-
spective study, Stassen et al. found that the incidence of
VTE associated with AAV was 1.8/100 person-years.
During active disease, defined as 3 months before and
after the diagnosis or relapse of AAV, the incidence in-
creased to 6.7/100 person-years. A total of 198 patients
aged from 14 to 81 years were analyzed in their study.
Of the 23 patients (12 %) with AAV, 17 had DVT, 3 had
PE, and 5 had both DVT and PE [4]. Previous studies
have mainly focused on adult patients with AAV, and
the same findings have also been noted in pediatric pa-
tients. One retrospective study in 2007 included 25
pediatric patients with Wegener’s granulomatosis, of
whom 4 patients developed VTE during follow-up, 3
with DVT and PE, and 1 with only DVT [10]. The
pathogenesis of AAV associated VTE remains unclear.
Neither classic risk factors for thromboembolic eventssuch as immobilization, trauma, malignancy, major surgery,
pregnancy, positive family history nor thrombophilia show
a significant prevalence in patients with AAV [6]. Several
mechanisms for VTE with AAV have been proposed in
previous studies. ANCAs stimulate neutrophil-induced
cytotoxicity toward endothelial cells, leading to vessel wall
inflammation, obliteration and damage. Other synergistic
effects of infection, genetics, and drugs (e.g. hydralazine, an-
tibiotics, non-steroidal drugs, cyclosporine, anti-thyroid
agents) can trigger AAV with diverse pathological roles
[11–13]. Moreover, complementary PR3 (cPR3) can also be
found in patients with AAV, especially in those with PR3-
ANCA. cPR3 targets plasminogen, and can delay the con-
version of plasminogen to plasmin. With an increasing dis-
solution time of fibrin clots, cPR3 can result in a higher
incidence of VTE [14]. These mechanisms can explain the
higher risk of VTE in patients with active AAV, and we sug-
gest that VTE can also be an important clue for higher
AAV disease activity.
When treating VTE in patient with AAV, both timely
immunosuppressive agents and anti-coagulants are im-
portant to achieve favorable outcomes. Strategies includ-
ing unfractionated heparin, low molecular weight heparin,
inferior vena cava filter, oral warfarin, and aspirin have
been reported when facing VTE in active AAV patients [5,
7, 8, 15]. In many clinical trials, the reduction in rates of
VTE recurrence were similar or even better in patients re-
ceiving low molecular weight heparin than in patients tak-
ing a combination of unfractionated heparin with a
vitamin K antagonist, and the bleeding rate was not statis-
tically different between these two groups [16]. The short-
term use of anti-coagulations is usually about 6 months,
while long-term use is often indicated for patients with re-
current or severe VTE, or with other acquired or genetic
risk factors for hypercoagulability.
The most appropriate intervention for patients with
AAV complicated with PH and VTE is a clinical dilemma,
and whether or not to stop anticoagulant therapy is a diffi-
cult decision. The benefits of anti-coagulation treatment
need to be balanced carefully against the potential risk of
bleeding. The use of anti-coagulation therapy may in-
crease the risk of PH, however the incidence is currently
unknown due to the small number of cases of AAV with
VTE and concurrent PH [7]. In previous studies, anti-
coagulation treatment was usually continued to prevent
further VTE even with active PH [7, 8]. In our case, we
decided to discontinue low molecular weight heparin due
to the active PH, and no further exacerbations of VTE
were found. Plasmapheresis has been demonstrated to be
beneficial in the presence of severe PH by removing
ANCAs and other circulatory factors such as inflammatory
cytokines, complement, and coagulation factors from the
systemic circulation [14, 17, 18]. Hence, Plasmapheresis is a
logistical and important therapeutic intervention for both
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plasmapheresis may prevent further PH and VTE when
these two complications occur simultaneously.
More aggressive therapy to induce remission may have
curtailed the relapse of AAV in this patient. According
to the European League Against Rheumatism (EULAR)
recommendations for small vasculitis, a combination of
corticosteroids and cyclophosphamide is the standard
strategy of care for AAV when attempting to induce re-
mission [19]. High-dose prednisolone at 1 mg/kg/day
should be used for at least 1 month, and methylprednis-
olone pulse therapy may also be used if a rapid effect is
needed [19]. Due to the family’s concerns of the side ef-
fects of cyclophosphamide in our case, we chose myco-
phenolate mofetil to induce remission. Mycophenolate
mofetil can be used to induce remission, and it has been
shown to achieve high complete remission rates in previ-
ous clinical trials [20–22]. We also chose prednisolone
at 1 mg/kg/day, and did not administer methylpredniso-
lone pulse therapy due to her relatively stable condition.
More aggressive therapy such as methylprednisolone
pulse therapy and cyclophosphamide may have led to
better disease control and fewer relapses. However, we
also needed to face the side effects of aggressive medica-
tion, and that decision was more difficult and less
convincing to the parents as the patient was nearly
symptom free at the end of the first admission.
The assessment of disease activity and predict the risk
of relapse in childhood AAV remains inconclusive. In our
case, we tested for MPO-ANCA several times, and the
level was not found to be correlated with clinical disease
severity. According to previous studies, MPO-ANCA is
much more prevalent in Chinese and Japanese patients
than in Caucasian patients with AAV [23, 24]. However,
compared to PR3-ANCA, which was independently asso-
ciated with a higher risk of relapse, the level of MPO-
ANCA did not seem to correlate with disease activity [25].
In adult patients with AAV, the Birmingham vasculitis ac-
tivity score (BVAS) has been validated as a comprehensive
multisystem disease activity assessment tool. A retrospect-
ive study published by Morishita et al. assessed the per-
formance of the BVAS for the diagnosis of children with
AAV. The median BVAS v.3 at the time of diagnosis (18.0
+ − 8.0) was similar to the mean BVAS v.3 reported in
adult patients with vasculitis, however the pediatric AAV
patients had higher scores for pulmonary and renal in-
volvement. Before the BVAS v.3 can be used as a disease
activity assessment tool in pediatric AAV, further modifi-
cations in weighting or changes to the ceiling scores may
be required [26]. In addition, Walsh et al. assessed 535
patients for the risk factors of a relapse in AAV, and
found that anti-PR3 positivity and cardiovascular in-
volvement were independently associated with the first
relapse, whereas neither BVAS score nor C-reactiveprotein level showed a correlation with the first relapse
[27]. Moreover, pulmonary-renal syndrome is defined as dif-
fuse alveolar hemorrhage and rapidly progressive glomer-
ulonephritis. Therefore, regularly monitoring hemoglobin
level, hematuria, proteinuria, and serum creatinine is im-
portant for further assessments [28, 29]. Other studies
have reported that patients with AAV have a higher inci-
dence of VTE, especially in the active stage [4, 5, 7, 15],
however VTE is not included in scoring disease activity in
the current BVAS. We suggest that VTE is a clue of active
AAV and should be included in further scoring systems to
more accurately assess disease activity. Overall, we suggest
that serum creatinine level, BVAS, falling hemoglobin level,
and episodes of VTE should all be taken into consideration
when assessing the disease activity of children with AAV.
The prophylactic anticoagulant therapy in patients with
AAV is in still under debate. Patients with AAV have a
higher incidence VTE. However, patients may also suffer
from PH or cerebral hemorrhage more frequently during
the active stage. Prophylactic anti-coagulation may therefore
not be safe or appropriate for every patient. If the patient
has recurrent or refractory thromboembolism, adequate
prophylactic anti-coagulation treatment may be helpful.
Whether or not to use prophylactic anti-coagulant agents
depends on the patient’s clinical condition. Further prospect-
ive studies are needed to develop reliable treatment guide-
lines for VTE in patients with AAV.
The strength of this report is that when facing the di-
lemma of concurrent PH and VTE, we used timely aggres-
sive therapy with methylprednisolone pulse therapy and
plasmapheresis and other supportive care to resolve PH
and keep VTE under control. The limitations of this study
are as following. First we did not perform angiography
of pulmonary computed tomography or a ventilation-
perfusion scan during the second hospitalization. It is
therefore difficult to completely rule out concurrent PE,
especially with the active PH. Second, we chose mycophe-
nolate mofetil instead of cyclophosphamide during the
first hospitalization after discussing the benefits and side
effects of both medications with the parents. We do not
know whether the outcome would have been better if we
had chosen cyclophosphamide for the initial induction re-
mission therapy.
Conclusion
AAV is an uncommon and multi-systemic disease in
children. The incidence of VTE is higher in patients
with AAV, and VTE can be an important clue of severe
active disease. When patients develop VTE, anti-
coagulation therapy is indicated to treat and prevent re-
current episodes. However, the treatment intervention
is challenging when facing complications of VTE and
concurrent PH, which can occur in a 14-year-old girl.
The administration of timely methylprednisolone pulse
Tseng et al. Pediatric Rheumatology  (2015) 13:20 Page 7 of 7therapy and plasmapheresis can decrease disease activ-
ity and lead to complete remission of both VTE and PH.
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